MAPT and Alzheimer disease: Therefore, the present study aimed to assess the potential clinical significance of GPNMB in the AD continuum, especially in patients with MCI, in relation to other neuroinflammatory biomarkers (YKL-40) and classical biomarkers of AD that reflect amyloid and tau pathologies.